Prostate cancer is one of the leading causes of male mortality. The prostate specific antigen (PSA) present in serum is a marker widely used in the early detection of prostate cancer. However, the specificity of PSA is limited, and biopsy is only positive in 25% of patients with serum PSA concentrations between 2 and 10 ng / mL. In situations in which the patient has a high PSA score (within the risk values) and a negative biopsy, it is recommended that the procedure be repeated according to the European Association of Urology.
ProPSA test consists of a paramagnetic particle chemiluminescence assay that determines the value of [-2] proPSA along with the concentrations of PSA and fPSA (free PSA) to calculate the multi-variable index of prostate health (PHI) designed to facilitate the determination of risk of prostate cancer using human serum.
PHI is used as a tool to distinguish patients at high risk for prostate cancer from those with benign prostatic conditions in the following situations: men aged 50 years and older with total PSA values between 2 and 10 ng / mL, evidence of rectal cancer.
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Non-invasive analysis, since it does not require tissue biopsy.
• Measurement of PHI increases the accuracy of prostate cancer detection compared to PSA or free PSA, especially in the group of patients with a PSA score between 2 and 10 ng/mL.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent.
• Clinical Questionnaire.
• It is not necessary fasting for the test.
• Serum sample should be obtained before performing prostatic manipulations such as rectal touch (DRE), prostate massage, transrectal ultrasound (TRUS) or prostatic biopsy.